ValenzaBio is a privately held, best-in-class biologics company with three differentiated product candidates and multiple additional discovery programs. Current product candidates are being developed for dermatologic, ophthalmic, and renal indications, and our hope is to launch our first medicine as soon as 2026.

Our product candidates utilize well-understood mechanisms of action, which minimizes clinical risk, and also feature biochemical properties that may make them superior to currently available therapies.

We’re using proven methods to develop medicines that provide true advantages to doctors and patients—and we’d love your help in fulfilling that mission! It’s an exciting time to be part of our company as we grow and advance our assets into the clinic.

Check out our current opportunities at the link below—or get in touch! We look forward to hearing from you.

View open jobs more
Young woman working hard picture

ValenzaBio at-a-glance

Company type

Biologics company developing first-in-class monoclonal antibody (mAb) therapies


Bethesda, MD

Year started


Number of employees


Development stage

Multiple product candidates from discovery to Phase 2

Lead product candidates/

VB421, anti-IGF-R1 mAb for thyroid eye disease
VB119, anti-CD-19 mAb for membranous neuropathy
VB517, anti-c-Kit mAb for chronic urticaria

Compensation and benefits

Generous salary and benefits packages

For more information


6701 Democracy Blvd.
Suite 300
Bethesda, MD 20817

First Name
Last Name